Shopping Cart

Expired activity

Please go to the PowerPak homepage and select a course.

FACULTY

Paul P. Dobesh, PharmD, FCCP, BCPS, BCCP
Professor of Pharmacy Practice and Science
University of Nebraska College of Pharmacy
Clinical Pharmacy Specialist, Cardiology
University of Nebraska Medical Center
Omaha, NE

Charles E. Mahan, PharmD, PhC, FCCP, FASHP
Adjunct Associate Professor of Pharmacy
University of New Mexico College of Pharmacy
Cardiac Critical Care Clinical Pharmacist
Presbyterian Healthcare Services
Albuquerque, NM

FACULTY BIOGRAPHY

Paul P. Dobesh, PharmD, FCCP, BCPS, BCCP
Professor of Pharmacy Practice and Science
University of Nebraska College of Pharmacy
Clinical Pharmacy Specialist, Cardiology
University of Nebraska Medical Center
Omaha, NE

Dr Paul P. Dobesh is Professor of Pharmacy Practice and Science at the University of Nebraska College of Pharmacy in Omaha and a Clinical Pharmacy Specialist in Cardiology at the University of Nebraska Medical Center (UNMC). He earned his Bachelor of Science in Pharmacy and Doctor of Pharmacy from South Dakota State University in Brookings, then went on to complete a residency in Internal Medicine at the University of Texas Brackenridge Hospital in Austin. Additionally, Dr Dobesh is a Fellow of the American College of Clinical Pharmacy.

Dr Dobesh’s research interests include antiplatelet and antihrombotic therapy with a focus on real-world utilization and health economics. He has written multiple book chapters and his articles have been published in peer-reviewed journals such as the American Journal of Managed Care, Pharmacotherapy, the Journal of Pharmacy Practice, the American Journal of Health-System Pharmacy, and the Journal of the American College of Cardiology. Dr Dobesh has been invited to present at national and international meetings, and he remains an active educator for the University of Nebraska, where he is responsible for teaching pharmacy and medical students as well as pharmacy and medical residents. He received the “Distinguished Educator of the Year” award from the UNMC College of Pharmacy in 2017, an award he has received 5 times since 2007

FACULTY BIOGRAPHY

Charles E. Mahan, PharmD, PhC, FCCP, FASHP
Adjunct Associate Professor of Pharmacy
University of New Mexico College of Pharmacy
Cardiac Critical Care Clinical Pharmacist
Presbyterian Healthcare Services
Albuquerque, NM

Dr Charles E. Mahan is an Adjunct Associate Professor of Pharmacy at the University of New Mexico College of Pharmacy in Albuquerque and a Cardiac Critical Care Clinical Pharmacist at Presbyterian Healthcare Services, also in Albuquerque. He earned his Bachelor of Science in Pharmacy and his Doctor of Pharmacy from the University of New Mexico. Dr Mahan also completed a traveling fellowship for the North American Thrombosis Forum at McMaster University in Hamilton, Ontario, Canada. Additionally, he is a Fellow of the American College of Chest Physicians and the American Society of Health-System Pharmacists (ASHP).

Dr Mahan is a key opinion leader at the national and international level in the area of antithrombotics, and his primary research interests are reduction of the incidence of preventable venous thromboembolism and stroke and appropriate transitions of care with antithrombotics. His research has led to several book chapters, abstracts, and published articles in peer-reviewed journals such as the American Journal of Health-System Pharmacy, Annals of Emergency Medicine, Journal of Thrombosis and Thrombolysis, and the American Journal of Medicine. Dr Mahan has delivered over 400 regional, national, and international presentations surrounding venous thromboembolism and new anticoagulants. He has served as Chair of the Council of Therapeutics for ASHP and is currently a voting member of the National Quality Forum’s Cardiovascular Standing Committee for the Cardiovascular Endorsement Maintenance Project of United States Performance Measures. Additionally, Dr Mahan is a preceptor for the University of New Mexico College of Pharmacy and a resident preceptor for Presbyterian Healthcare Services.

FINANCIAL DISCLOSURE

Paul P. Dobesh, PharmD, FCCP, BCPS, BCCP, hereby states that he has the following relevant affiliation or financial relationship or relationship to products or devices with a commercial interest related to the content of this activity to disclose:

Consultant – Boehringer Ingelheim Pharmaceuticals, Inc; Bristol-Myers Squibb/Pfizer Alliance; Daiichi Sankyo, Inc; Janssen Pharmaceuticals, Inc; Portola Pharmaceuticals, Inc

Charles E. Mahan, PharmD, PhC, FCCP, FASHP, hereby states that he has the following relevant affiliation or financial relationship or relationship to products or devices with a commercial interest related to the content of this activity to disclose:

Consultant – Janssen Pharmaceuticals, Inc; Portola Pharmaceuticals, Inc
Speaker’s Bureau – Bristol-Myers Squibb/Pfizer Alliance; Janssen Pharmaceuticals, Inc; Portola Pharmaceuticals, Inc

The following reviewer, Catherine A. Sheffield, PharmD, BCPS, has indicated that she has no financial relationships or relationships to products or devices with any commercial interest related to the content of this activity.

Susanne Batesko, RN, BSN, Robin Carrino, Mairead Early, Kate Evans, Cara U, PharmD, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE)/Spire Learning continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

ACCREDITATION STATEMENTS

PHARMACY
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN:  0430-9999-19-102-H01-P
Credits: 1.0 hours (0.10 ceu)

Type of Activity: Knowledge
Media: Internet

Fee Information: There is no fee for this educational activity.

Estimated time to complete activity: 60 minutes

Published

November 27, 2019

Expires

November 27, 2020

TARGET AUDIENCE

This accredited activity has been designed for pharmacists with an interest in the reversal of bleeding associated with factor Xa inhibitors.

HOW TO EARN CREDIT

During the period November 27, 2019, through November 27, 2020, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the posttest and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Grade Exam at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

GOAL

To educate pharmacists about the recommendations for assessment and management of bleeds associated with factor Xa inhibitors and appropriate reinitiation of anticoagulation after a bleed.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants should be better able to:

1. IDENTIFY the signs and symptoms of severe bleeding in patients receiving factor Xa inhibitor therapy
2. DISCUSS measurement of anticoagulant activity in individuals who present with factor Xa inhibitor-associated bleeding or who require emergency surgery
3. RECOGNIZE appropriate reversal agents based on the type of anticoagulant, dose, timing of last dose, and indication
4. DEFINE optimal timing of anticoagulant reinitiation

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer system you plan to use meets the following minimum requirements:

• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
• Peripherals: Computer speakers or headphones
• Monitor Screen Resolution: 320 x 480 or higher
• Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, Spire Learning, and Portola Pharmaceuticals. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without an evaluation of their patients’ conditions and current medications, including the identification of possible contraindications regarding the dangers of use and a review of any applicable manufacturer’s product information, as well as a comparison with the recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer’s package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.